ru-28362 has been researched along with canrenone in 1 studies
| Studies (ru-28362) | Trials (ru-28362) | Recent Studies (post-2010) (ru-28362) | Studies (canrenone) | Trials (canrenone) | Recent Studies (post-2010) (canrenone) |
|---|---|---|---|---|---|
| 175 | 0 | 3 | 268 | 39 | 59 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Briski, KP; Sylvester, PW | 1 |
1 other study(ies) available for ru-28362 and canrenone
| Article | Year |
|---|---|
Antagonism of type II, but not type I glucocorticoid receptors results in elevated basal luteinizing hormone release in male rats.
Topics: Androstanols; Animals; Canrenone; Glucocorticoids; Luteinizing Hormone; Male; Mifepristone; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid | 1994 |